Belantamab mafodotin
Based on 1 publication(s) in Google Scholar
Belantamab mafodotin (GSK2857916) is composed of humanized and focused monoclonal antibody against B cell maturation antigen (BCMA) and McMMAF. The antibody portion is Belantamab (HY-P9980), and the drug-linker conjugate for ADC is McMMAF (HY-15578). Belantamab mafodotin has anti-myeloma activity.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 99.67%
- CAS No.: 2050232-20-5
- Masse moléculaire:149000 (average)
-
Stockage:
-80°C, protect from light
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
- Pureté et documentation
- Références
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Belantamab mafodotin
More
Activité biologique
Belantamab mafodotin binds to human BCMA protein with a Kd of 1 nM[2].
Belantamab mafodotin induces G2/M arrest in multiple myeloma cells in a dose and time dependent manner[2].
Belantamab mafodotin signifcantly promotes phagocytosis of multiple myeloma cells by human macrophages derived from macrophage colony-stimulating factor-stimulated monocytes[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Mice harbouring OPM2 tumours[2]
-
Dosage:4 mg/kg
-
Administration:IP, twice weekly for 4 doses
-
Result:Signifcantly improves survival compared to vehicle.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 2050232-20-5
-
Appearance Liquid
-
Masse moléculaire 149000 (average)
-
Color Colorless to light yellow
-
SMILES
[Belantamab mafodotin]
-
Synonyms
GSK2857916; Belantamab mafodotin-blm
-
Livraison
Shipping with dry ice.
-
Stockage
-80°C, protect from light
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Neoplasia
Rational payload selection enables high antitumoral efficacy of an anti-EGFR antibody-drug conjugate against ovarian tumors. [Abstract]2026 Mar 12:74:101295. PMID: 41825107
Pureté et documentation
-
Fiche technique (268 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Hulin C, et al. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study. Lancet Oncol. 2020 Feb;21(2):207-221. [Content Brief]
[2]. Markham A. Belantamab Mafodotin: First Approval. Drugs. 2020 Oct;80(15):1607-1613. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Belantamab mafodotin Related Classifications
HY-P3239 Related Classifications
Powered by Bioz